Leerink downgraded Aurinia Pharmaceuticals (AUPH) to Market Perform from Outperform with a price target of $16, up from $15. While Aurinia has done well with the commercialization of Lupkynis in lupus nephritis, the product is unlikely to be as big as the firm originally thought and there is some uncertainty regarding the tail of this asset, the analyst tells investors in a research note. Additionally, while Leerink views the aritinercept data favorably, it is coming from behind in a crowded development landscape, and the firm lacks visibility into its differentiation and competitive moat.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUPH:
- Aurinia Pharmaceuticals downgraded to Market Perform from Outperform at Leerink
- Aurinia Pharmaceuticals upgraded to Buy from Hold at Jefferies
- Aurinia Pharmaceuticals Reports Strong Q3 2025 Earnings
- Aurinia Pharma’s Earnings Call Highlights Growth and Challenges
- Aurinia downgraded to Sector Perform from Outperform at RBC Capital